These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17534953)

  • 1. Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy.
    Warren NM; Piggott MA; Greally E; Lake M; Lees AJ; Burn DJ
    Mov Disord; 2007 Aug; 22(11):1594-600. PubMed ID: 17534953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases.
    Warren NM; Piggott MA; Lees AJ; Burn DJ
    J Neurol Neurosurg Psychiatry; 2007 Jun; 78(6):571-5. PubMed ID: 17178818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease.
    Piggott MA; Owens J; O'Brien J; Colloby S; Fenwick J; Wyper D; Jaros E; Johnson M; Perry RH; Perry EK
    J Chem Neuroanat; 2003 Mar; 25(3):161-73. PubMed ID: 12706204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
    Im JH; Chung SJ; Kim JS; Lee MC
    J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.
    Chinaglia G; Alvarez FJ; Probst A; Palacios JM
    Neuroscience; 1992 Jul; 49(2):317-27. PubMed ID: 1436470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholinergic vesicular transporters in progressive supranuclear palsy.
    Suzuki M; Desmond TJ; Albin RL; Frey KA
    Neurology; 2002 Apr; 58(7):1013-8. PubMed ID: 11940684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary studies of differential impairments of the dopaminergic system in subtypes of progressive supranuclear palsy.
    Lin WY; Lin KJ; Weng YH; Yen TC; Shen LH; Liao MH; Lu CS
    Nucl Med Commun; 2010 Nov; 31(11):974-80. PubMed ID: 20717064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy.
    Landwehrmeyer B; Palacios JM
    J Neural Transm Suppl; 1994; 42():229-46. PubMed ID: 7525868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotensin receptors in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study in basal ganglia.
    Chinaglia G; Probst A; Palacios JM
    Neuroscience; 1990; 39(2):351-60. PubMed ID: 1965015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography.
    Messa C; Volonté MA; Fazio F; Zito F; Carpinelli A; d'Amico A; Rizzo G; Moresco RM; Paulesu E; Franceschi M; Lucignani G
    Eur J Nucl Med; 1998 Sep; 25(9):1270-6. PubMed ID: 9724376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
    Kim YJ; Ichise M; Ballinger JR; Vines D; Erami SS; Tatschida T; Lang AE
    Mov Disord; 2002 Mar; 17(2):303-12. PubMed ID: 11921116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy.
    Pierot L; Desnos C; Blin J; Raisman R; Scherman D; Javoy-Agid F; Ruberg M; Agid Y
    J Neurol Sci; 1988 Sep; 86(2-3):291-306. PubMed ID: 2975699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscarinic receptors in the thalamus in progressive supranuclear palsy and other neurodegenerative disorders.
    Warren NM; Piggott MA; Lees AJ; Burn DJ
    J Neuropathol Exp Neurol; 2007 May; 66(5):399-404. PubMed ID: 17483697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinergic systems in progressive supranuclear palsy.
    Warren NM; Piggott MA; Perry EK; Burn DJ
    Brain; 2005 Feb; 128(Pt 2):239-49. PubMed ID: 15649952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.
    Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS
    J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intact coupling of M1 receptors and preserved M2 and M4 receptors in the cortex in progressive supranuclear palsy: contrast with other dementias.
    Warren NM; Piggott MA; Lees AJ; Perry EK; Burn DJ
    J Chem Neuroanat; 2008 May; 35(3):268-74. PubMed ID: 18282687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease.
    Ilgin N; Zubieta J; Reich SG; Dannals RF; Ravert HT; Frost JJ
    Neurology; 1999 Apr; 52(6):1221-6. PubMed ID: 10214747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
    Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [125I]EGF binding in basal ganglia of patients with Parkinson's disease and progressive supranuclear palsy and in MPTP-treated monkeys.
    Villares J; Faucheux B; Herrero MT; Obeso JA; Duyckaerts C; Hauw JJ; Agid Y; Hirsch EC
    Exp Neurol; 1998 Nov; 154(1):146-56. PubMed ID: 9875276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
    J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.